PUK4 A Cost-Comparison Analysis of Treating Overactive Bladder (OAB) With Fesoterodine, Tolterodine or Solifenacin in Daily Clinical Practice in Spain
A. Sicras-Mainar, J. Rejas, R. Navarro-Artieda, A. Aguado-Jodar, A. Ruiz-Torrejón, M.G. KvaszVolume:
15
Year:
2012
Language:
english
DOI:
10.1016/j.jval.2012.08.1442
File:
PDF, 61 KB
english, 2012